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Abstract
Background:  TSPY is a repeated gene mapped to the critical region harboring the
gonadoblastoma locus on the Y chromosome (GBY), the only oncogenic locus on this male-specific
chromosome. Elevated levels of TSPY have been observed in gonadoblastoma specimens and a
variety of other tumor tissues, including testicular germ cell tumors, prostate cancer, melanoma,
and liver cancer. TSPY contains a SET/NAP domain that is present in a family of cyclin B and/or
histone binding proteins represented by the oncoprotein SET and the nucleosome assembly
protein 1 (NAP1), involved in cell cycle regulation and replication.
Methods:  To determine a possible cellular function for TSPY, we manipulated the TSPY
expression in HeLa and NIH3T3 cells using the Tet-off system. Cell proliferation, colony formation
assays and tumor growth in nude mice were utilized to determine the TSPY effects on cell growth
and tumorigenesis. Cell cycle analysis and cell synchronization techniques were used to determine
cell cycle profiles. Microarray and RT-PCR were used to investigate gene expression in TSPY
expressing cells.
Results:  Our findings suggest that TSPY expression increases cell proliferation in vitro and
tumorigenesis in vivo. Ectopic expression of TSPY results in a smaller population of the host cells in
the G2/M phase of the cell cycle. Using cell synchronization techniques, we show that TSPY is
capable of mediating a rapid transition of the cells through the G2/M phase. Microarray analysis
demonstrates that numerous genes involved in the cell cycle and apoptosis are affected by TSPY
expression in the HeLa cells.
Conclusion:  These data, taken together, have provided important insights on the probable
functions of TSPY in cell cycle progression, cell proliferation, and tumorigenesis.
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Background
The testis specific protein Y-encoded (TSPY) gene was one
of the early genes to be identified from the human Y chro-
mosome [1,2]. TSPY is embedded in a 20.4-kb DNA frag-
ment that is tandemly repeated ~35 times in humans [3].
The 2.8-kb TSPY transcriptional unit consists of six exons
and 5 introns distributed primarily on the short arm of the
Y chromosome [2,4]. The bovine Y chromosome contains
50–200 copies of TSPY, while the rat Y chromosome con-
tains a single copy. The mouse possesses a nonfunctional
Tspy gene, on its Y chromosome, that harbors several stop
codons within its open reading frame [5-7]. The human
TSPY is expressed in both fetal and adult testes [2,4,8]. It
is localized in the cytoplasm and nucleus of embryonic
gonocytes and adult spermatogonial cells [4,8]. In partic-
ular, the spermatogonial cells are the only cells in the
male capable of entering both mitotic and meiotic cell
division. The exact function of the TSPY gene product is
thus far unknown. It has been hypothesized to regulate
the normal proliferation of spermatogonia and marks the
entry of the spermatogonia into the meiotic differentia-
tion [9].
TSPY is expressed in adult testis as a phosphoprotein with
an apparent molecular weight of 38 kD [4]. It harbors a
SET/NAP domain, conserved among members of a pro-
tein family, represented by the SET oncoprotein and
nucleosome assembly protein-1 (NAP-1) respectively.
Major members of this protein family include SET, NAP-
1, TSPY, differentially expressed nucleolar TGF-β1 target
(DENTT) [10,11]/cell division autoantigen-1 (CDA1)
[12]/TSPX [13]. SET was initially identified in a patient
with acute undifferentiated leukemia, who harbored an
intrachromosomal translocation on chromosome 9 [14-
16] and demonstrated to bind B-type cyclins [17]. SET reg-
ulates the G2/M transition by modulating cyclin B-cyclin-
dependent kinase 1 (CDK1) activity [18]. NAP-1 interacts
with B-type cyclins in budding yeast and frogs [17]. In Sac-
charomyces cerevisiae, cells that lack NAP-1, the Clb2 (B-
type cyclin) was unable to efficiently induce mitotic
events [19,20]. Over-expression of SET or CDA1 results in
an inhibitory effect on cell cycle progression at the G2/M
phase [18], suggesting that SET/NAP-containing proteins
are cell cycle regulators.
Deletion mapping for the gonadoblastoma locus on the Y
chromosome (GBY) [21] has localized this oncogenic
locus in a critical region (~1–2 Mb) on the short arm of
this chromosome that contains most of the functional
copies of the TSPY gene [22,23]. Elevated levels of TSPY
protein have been observed in gonadoblastoma, thereby
providing supporting evidence for TSPY as a likely candi-
date for the GBY [4,9,24,25]. TSPY is also expressed in tes-
ticular carcinoma-in-situ (CIS) [4,25], seminomas [24],
prostate cancer specimens/cell lines [26-28], melanomas
[29] and hepatocellular carcinoma [30]. To test the
hypothesis that TSPY is involved in cell cycle regulation
and its aberrant expression could contribute to the overall
tumorigenesis, we have examined the effects of ectopic
expression of TSPY in cell proliferation and tumorigenesis
in athymic nude mice, using the tetracycline (Tet-off) reg-
ulation system in human HeLa and mouse NIH3T3 cells
[31]. Our results suggest that ectopic expression of TSPY
increases cell proliferation in vitro and tumorigenesis in
vivo. Expression of TSPY expedites the transition of the
cells through the G2/M phase of the cell cycle, indirectly
up-regulates pro-growth genes and down-regulates apop-
tosis inducing molecules and growth inhibitory genes,
thereby promoting cell proliferation in both cell cultures
and whole animals.
Methods
Plasmids and stable cell transfection
The TSPY cDNA [2] was inserted at the EcoR1 site of the
bicistronic vector, pTRE-IRES-GFP (designated as pTIG).
The resulting construct (pTIG-TSPY) is capable of express-
ing both TSPY and EGFP under control of a modular tet-
racycline-responsive promoter. HeLa and NIH3T3 Tet-off
cells harboring a stably integrated tetracycline transactiva-
tor gene were purchased from Clontech-BD BioSciences
(Mountain View, CA). They were cultured in DMEM
media containing 10% fetal bovine serum (FBS), 1% pen-
icillin/streptomycin (P/S), and 400 μg/ml G418 (Invitro-
gen-Life Technologies, Carlsbad, CA) at 37°C in 5% CO2.
To generate stable cell lines conditionally expressing
TSPY, the Tet-off cells were co-transfected with the pTIG-
TSPY or pTIG vector and the hygromycin resistance
marker, pTK-Hyg, at a ratio of 20:1, using either the Lipo-
fectamine Plus (Invitrogen-Life Technologies, Carlsbad,
CA) or FuGene6 (Roche, Alameda, CA) reagents, accord-
ing to the instructions of the respective manufacturers.
The cells were selected with the complete medium plus
300  μg/ml hygromycin (Invitrogen-Life Technologies,
Carlsbad, CA) at a density of 4 × 105 cells per 100 mm cul-
ture dish. Cell colonies were selected with or without 2
ng/ml doxycycline (Dox) (Sigma, St. Louis, MO) in the
selective media for 2–3 weeks. Positive colonies were iso-
lated individually and clonally expanded as sub-lines.
Alternatively, the colonies were pooled and isolated by
preparative flow cytometry based on their EGFP expres-
sion using a FACSVantage SE Cell Sorter (Becton Dickin-
son, Frankilin Lakes, NJ) at the Laboratory for Cell
Analysis, Cancer Center, University of California, San
Francisco. Cells expressing EGFP were collected on ice in
fresh media and immediately re-plated in culture dishes
with complete media. Cells isolated with either strategy
were then analyzed for their responsiveness to doxycy-
cline regulation of their TSPY and EGFP transgenes usingBMC Cancer 2006, 6:154 http://www.biomedcentral.com/1471-2407/6/154
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western blotting and fluorescence microscopy respec-
tively.
Immunofluorescence and western blotting
EGFP expression in cultured cells was observed directly
under a Zeiss Axiophot fluorescence microscope using an
excitation filter HQ 480/40 and an emission filter HQ 510
LP (Chroma Technology Corp., Rockingham, VT). TSPY
expression was detected by indirect immunofluorescence
according to established procedures. The cells were
stained with a polyclonal TSPY antiserum [9] at 1:100
dilution at 4°C overnight, rinsed 3 times with PBS, incu-
bated with a goat anti-rabbit IgG antibody conjugated to
Texas Red (1:1000 dilution) for 30 minutes at room tem-
perature, and analyzed with the Zeiss fluorescence micro-
scope and appropriate filter set for Texas Red.
Western blotting of total cell lysates from HeLa or NIH3T3
Tet-off cells grown in the presence or absence of 2 ng/ml
Dox was processed according to established procedures,
using TSPY antisera and monoclonal antibodies, as
described previously[32]. Immunoblot signals were
detected by enhanced chemiluminescence (ECL) tech-
nique (Amersham, Piscataway, NJ).
Cell proliferation analysis
Cell proliferation was analyzed by XTT assay, based on the
cleavage of the tetrazolium salt XTT in the presence of an
electron-coupling reagent by the succinate-tetrazolium
reductase whose activity was directly associated with
number of viable cells. HeLa or NIH3T3 Tet-off cells sta-
bly transfected with pTIG-TSPY or pTIG were grown on
100 mm dishes in culture media in the presence or
absence of 2 ng/ml doxycycline for 3 days. Cells were then
seeded at a concentration of 5 × 103 cells/well in 100 μl
culture media with or without Dox on a 96-well microtiter
plate, incubated at 37°C with 5% CO2 and analyzed in
triplicates at 24 h intervals for 4 days. Fifty μl XTT labeling
mixture was added to each well 4 hours before each spec-
trometric measurement.
Colony formation assay
HeLa and NIH3T3 Tet-off cells were transfected with
either pTIG-TSPY or pTIG plasmid and cultured for 3
weeks in a selective medium containing 300 μg/ml hygro-
mycin and with or without 2 ng/ml Dox. The resulting
colonies were stained with Giemsa and counted manu-
ally. Each 100 mm dish represented 1:10 dilution of cells
from a single well, which had been transfected with 1 μg
of TIG-TSPY or vector and 0.05 μg pTK-Hyg selectable
marker.
Tumorigenicity assay in athymic nude mice
Female 8-week old athymic nu/nu mice (Charles River
Laboratories, Wilmington, MA) were used for tumori-
genicity assays. Subconfluent and exponentially growing
monolayer cells of each cell line were trypsinized, washed
and resuspended in PBS. One million TSPY-transfected
HeLa cells or 10 millions of similarly transfected NIH3T3
cells in 100 μl PBS were inoculated subcutaneously into
the flanks of the nude mice. Control cells, transfected with
pTIG or non-transfected parental cells, were inoculated
similarly. Six animals were used for inoculation of each
cell type. The mice were fed with drinking water with or
without 2 μg/ml of doxycycline. Tumor growth was meas-
ured by the tumor volume, in mm3, estimated from the
length (L) and width (W) of the tumors and the formula
(L × W2)/2 [33]. The tumorigenicity assays were termi-
nated by sacrificing the mice at 5 weeks (for HeLa cells) or
7 weeks (for NIT3T3 cells) after inoculation. All animal
studies were conducted under an approved protocol by
the Institutional Animal Care and Use Committee of the
VA Medical Center, San Francisco.
Cell synchronization and cell cycle analysis
Equal number of HeLa Tet-off cells stably transfected with
either pTIG-TSPY or pTIG were grown overnight, washed
with PBS, and fed with fresh media containing 2.5 mM
thymidine (for G1/S synchronization) or 80 ng/ml col-
cemid (for M phase synchronization) [34,35]. Cells were
synchronized in the respective media for 24 hours,
washed 3 times with PBS and released into fresh complete
media. At specific time points, the media was removed
and the cells were washed in PBS, trypsinized, collected,
washed again in PBS, placed in 1–3 ml of ice cold 70%
ethanol and incubated at -20°C for 1 hour – overnight.
Cells were then incubated in 10 μg/ml propidium iodide/
0.1% Triton X-100/0.1% RNase in PBS solution at 37°C
for 30 minutes in the dark. They were resuspended in 0.5
ml PBS and analyzed with a FACSCalibur flow cytometer
at the Laboratory for Cell Analysis, UCSF Cancer Center.
Cell cycle analysis was performed using ModFit LT (Verity
Software House, Topsham, ME), FlowJo (Tree Star, Ash-
land, OR), and Openlab (Improvision, Lexington, MA)
software.
Microarray analysis of gene expression profiles
Total RNA was isolated from respective cell populations
with TRIzol reagent (Invitrogen, Carlsbad, CA) and puri-
fied with RNeasy Mini Kit (Qiagen, Valencia, CA) in
accordance with the manufacturer's instructions. The
quality of RNA was assessed using the Agilent 2100 Bioan-
alyzer (Agilent Technologies, Palo Alto, CA). Five μg of
RNA was converted into double-stranded cDNA using a
cDNA synthesis kit (Affymetrix, Santa Clara, CA) with a
special oligo(dT)24 primer containing a T7 RNA promoter
site added 3' to the poly(T) tract. Biotinylated cRNAs were
generated from cDNAs using the bioarray high yield RNA
transcript labeling kit (Enzo Life Science, Farmingdale,
NY) and subsequently purified with the RNeasy kit (Qia-BMC Cancer 2006, 6:154 http://www.biomedcentral.com/1471-2407/6/154
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gen, Valencia, CA). Complementary RNA probe derived
from each sample was fragmented and hybridized to
GeneChip® Human Genome U133 Plus 2.0 Array contain-
ing 47,000 transcripts and variants using the Affymetrix
GeneChip Fluidics Station 450. Arrays were scanned by an
Affymetrix Gene Scanner 3000, the image files were proc-
essed using Microarray Analysis Suite version 5.0 (Affyme-
trix, Santa Clara, CA). Each biological sample was
analyzed with three technical replicates. All the 54,675
gene spots were filtered based on spot quality, statistical
test and corrections before subsequent analyses. To iden-
tify differentially expressed transcripts, all spots were first
normalized by scaling total chip fluorescence intensity to
a common value of 100 prior to comparison, and a nor-
malization value was set at 1. To minimize the potential
false-positives using t-test alone, the t-test p-value of each
gene when performing a statistical test was corrected by
multiple testing corrections, which adjust the individual
p-value for each gene to keep the overall error rate (or false
positive rate) to less than or equal to a cutoff at p < 0.005.
Multiple testing corrections based on Bonferroni step-
down method were used. The corrected p-value is calcu-
lated and considered to be significant if it is less than 0.05.
The false discovery rate applied in the tests was 5%. Data
and statistical analyses were performed with Genespring
7.0 software (Silicon Genetics, Redwood City, CA).
Semi-quantitative RT-PCR was used to validate genes dif-
ferentially expressed from data obtained with microarray
analysis, as described previously [27]. The primers were
derived from the corresponding cDNA sequences capable
of amplifying roughly 100 to120-bp fragments from tran-
scripts of the respective genes (Table 1). GADPH was
included as a control in all the RT-PCR experiments. The
number of cycle for each sample was independently deter-
mined to insure the reaction was terminated during the
exponential phase of the amplification. PCR reaction
products were separated on 1.5% agarose gels using ethid-
ium bromide for visualization. The relative abundance of
each PCR product was determined by quantitative analy-
sis of digital photographs of the gels viewed under UV
light (LabWorks software; UVP, Inc.).
Results
Tet-off regulation of TSPY gene expression
TSPY has been hypothesized to play a role(s) in regulation
of germ cell proliferation and meiotic division. When it is
ectopically expressed in cells incompatible with germ cell
proliferation and/or division, it exerts a yet-to-be defined
oncogenic effect(s) and contributes to the overall tumori-
genic process(es) in susceptible cells of the affected organ/
tissue [9,24,28]. To evaluate the effects of such ectopic
TSPY expression, we had used the Tet-off transgene regu-
lation system to manipulate its expression in HeLa and
NIH3T3 cells [31]. HeLa cells are human female cervical
carcinoma cells without the Y chromosome (and hence
TSPY genes) while the NIH3T3 cells are normal (non-
tumorigenic) mouse fibroblastic cells. Using the bicis-
tronic vector, TIG, we were able to demonstrate that both
TSPY and EGFP could be co-expressed in the same stably
transfected cells (Figure 1A, B) and could be manipulated
with the addition of doxycycline in the culture media (Fig-
ure 1C, D). EGFP was distributed relatively evenly among
different compartments of most cells, while TSPY was
located primarily in the cytoplasm and lightly in the
nuclei. A small portion of cells, however, showed substan-
tial nuclear localization or aggregated distribution of the
TSPY protein (Figure 1F, H, arrows). Similar nuclear loca-
tion of TSPY had been observed in various tumor speci-
mens [9,25]. A recent report suggests that a CD2-
dependent phosphorylation of the tyrosine reside at posi-
tion 300 of the predominant TSPY isoform is essential for
Table 1: Gene-specific primers used in semi-quantitative RT-PCR analysis
Gene Primers Sequences
RGC32 Forward GAGCGCCACTTCCACTACG
Reverse AGTGAATCTGCACTCTCCGAG
PDGFC Forward ACTCAGGCGGAATCCAACC
Reverse CTTGGGCTGTGAATACTTCCATT
WNT5A Forward TTGGTGGTCGCTAGGTATGAA
Reverse AGTGGCACAGTTTCTTCTGTC
CCND2 Forward AGGCGGTGCTCCTCAATAG
Reverse TATCCCGCACGTCTGTAGGG
CUL1 Forward ACCAGTCAAACCAAGCACGAG
Reverse GTCTGCCCCTTTTTCGACTTAG
IGFBP3 Forward AGAGCACAGATACCCAGAACT
Reverse TGAGGAACTTCAGGTGATTCAGT
TIMP1 Forward CTTCTGCAATTCCGACCTCGT
Reverse CCCTAAGGCTTGGAACCCTTT
SPARC Forward AGCACCCCATTGACGGGTA
Reverse GGTCACAGGTCTCGAAAAAGCBMC Cancer 2006, 6:154 http://www.biomedcentral.com/1471-2407/6/154
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A-H) Tet-off regulation of TSPY and EGFP expression in HeLa cells Figure 1
A-H) Tet-off regulation of TSPY and EGFP expression in HeLa cells. A bicistronic transgene capable of expressing both TSPY 
and EGFP in the same transcriptional unit was stably transfected to HeLa Tet-off cells. EGFP fluorescence (A) and TSPY (B) 
were detected by direct observation and immunofluorescence respectively. Such expression (i.e. EGFP in C) could be sup-
pressed by administration of doxycycline in the culture media (D). EGFP was located in both cytoplasm and nuclei of the host 
cells (E, G) while TSPY could display scattered locations along the periphery and within the nuclei, in addition to its cytoplasmic 
distribution (F, H, blue arrows). I-L) Effects of TSPY expression in cell transfection efficiency and proliferation in HeLa and 
NIH3T3 Tet-off cells. HeLa (I) and NIH3T3 (J) Tet-off cells were co-transfected with either TIG-TSPY (TSPY) construct or the 
vector pTIG alone with the TK-Hyg plasmid and were selected in culture media with hygromycin with (+) or without (-) doxy-
cyclinc (Dox). Both HeLa (I) and NIH3T3 (J) cells expressing TSPY (i.e. TSPY without doxycycline) consistently formed higher 
numbers of colonies than those repressing the same transgene (i.e. TSPY with doxycycline) while those expressing EGFP in the 
vector (pTIG) alone did not show any differences in the transfection efficiency in the absence or presence of doxycycline. Cell 
proliferation assays demonstrated that HeLa (K) and NIH3T3 (L) Tet-off cells over-expressing TSPY (without doxycycline) 
proliferated at a faster rate(s) than those repressing the TSPY gene (with doxycycline). Again, cells harboring the vector (pTIG) 
alone did not show any difference in their proliferative activities in media with or without doxycycline. Bars in D and H repre-
sent 40 μM in A-D and 10 μM in E-H respectively. * Student's t-test analysis indicated that there were statistical significance in 
differences between TSPY-expressing cells and vector-alone cells.
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its nuclear translocation [36]. Currently, the significance
of such differential distribution of TSPY in the cell com-
partments is uncertain. The present results demonstrate
that the TSPY and EGFP are expressed abundantly and
manipulated effectively with the Tet-off system in stably
transfected HeLa and NIH3T3 cells.
Over-expression of TSPY increases the colony formation 
efficiency and cell proliferation
To determine the effects of ectopic TSPY expression in cell
growth, the transfection efficiency of the pTK-Hyg marker
was determined in combination with either the TIG-TSPY
construct or TIG vector in HeLa and NIH3T3 Tet-off cells.
Approximately 3-fold higher numbers of colonies were
observed in TIG-TSPY transfected cells selected without
the doxycycline, i.e. over-expressing TSPY and EGFP, over
identically transfected cells selected in media containing
doxycycline, i.e. repressing the TSPY and EGFP expression
(Figure 1I, J, left panel). Such differential efficiency of col-
ony formation was absent in cells transfected with the TIG
vector alone either with or without doxycycline in the
selection media (Figure 1I, J, right panel). Although we
cannot rule out completely that co-expression of TSPY
might enhance the TK-Hyg gene expression, these results,
and those from cell proliferation analysis described
below, suggested that over-expression of TSPY enhances
the efficiency of cell growth under such selection.
To evaluate the effects of TSPY expression in cell prolifer-
ation, TIG-TSPY, TIG transfected cells and the respective
parental cells were analyzed with the XTT cell prolifera-
tion assay. Both HeLa and NIH3T3 Tet-off cells over-
expressing TSPY-EGFP showed consistently 30–45%
higher proliferative activities than those whose transgenes
were repressed by doxycycline. Cells transfected with the
vector alone, similar to the parental cells, did not show
any proliferative differences in the presence or absence of
doxycycline in the media (Figure 1K and 1L). These find-
ings suggest that ectopic expression of TSPY potentiates
cell proliferation in cultured cells.
TSPY expression accelerates tumor growth in nude mice
Tumorigenicity assay was used to correlate the prolifera-
tive effects of TSPY in cultured cells to those in whole ani-
mals. HeLa Tet-off cells transfected with either TIG-TSPY
or TIG vector alone and parental cells were inoculated
subcutaneously on the flanks of female athymic nude
mice. The mice were fed with drinking water either with or
without doxycycline for 5 weeks. The size of tumors
formed at the inoculation site was measured with stand-
ard procedure at the respective time points (Figure 2A, B).
An accelerated tumor growth was observed in mice inocu-
lated with HeLa Tet-off cells over-expressing TSPY (with-
out doxycycline in their drinking water) compared to the
group repressing TSPY (with doxycycline in their drinking
water). No accelerated tumor growth was observed in the
parental or the groups inoculated with HeLa cells harbor-
ing the vector alone, with or without doxycycline in their
drinking water. These results suggested that ectopic
expression of TSPY increased tumor growth in athymic
nude mice.
NIH3T3 cells are established mouse fibroblasts that nor-
mally do not form tumors in athymic animals. Using a
similar tumorigenicity assay, small size tumors were
observed in 5 out of 6 mice inoculated each with about 10
millions cells harboring and expressing TIG-TSPY (with-
out doxycycline in drinking water), while no tumors were
observed in the group of animals inoculated with similar
number of transfected cells, but fed with doxycycline in
their drinking water (Figure 2D, E). Again, mice inocu-
lated with the NIH3T3 cells transfected with vector alone
or the parental cells did not show any tumor formation,
with or without doxycycline in their drinking water. The
expression of the TSPY-EGFP transgene in the tumors of
these nude mice, fed with normal drinking water, could
be confirmed by direct observation of EGFP fluorescence
in the whole animals (Figure 2C, F).
TSPY expedites a rapid transition of G2/M of the cell cycle
Members of the SET/NAP family of proteins had been
demonstrated to bind type B cyclins and exert biological
effects on cell cycle progression. Our study, so far, showed
that ectopic expression of TSPY in HeLa and NIH3T3 cells
potentiated cell proliferation in vitro and tumor growth in
nude mice. To evaluate the likely cell cycle stage(s) in
which TSPY affected its pro-growth function, both expo-
nentially growing and synchronized HeLa Tet-off cells
harboring either the TIG-TSPY transgene or TIG vector
alone were analyzed with flow cytometry techniques.
Exponentially growing HeLa Tet-off cells harboring the
vector alone showed similar patterns in their cell cycle dis-
tribution when they were grown in the presence or
absence of doxycycline (Figure 3A) while those over-
expressing TSPY showed a small portion of its cells in the
G2/M phase (Figure 3B, red line). When expression of the
TSPY transgene was repressed with doxycycline in the
media (Figure 3B, blue line), the distribution of cells
among the different stages of the cell cycle was similar to
those of control cells (Figure 3A).
To determine why there was fewer number of TSPY
expressing HeLa Tet-off cells at G2/M phase, as compared
to HeLa Tet-off harboring the vector alone, the cells were
examined further with cell synchronization and cell cycle
analysis with flow cytometry. Cells were synchronized at
the G1/S boundary, released into the S phase and analyzed
with flow cytometry thereafter at 0, 6, 12, 24, 36 and 48
hours. The relative percents of the cells distributed at dif-
ferent stages (G1, S and G2/M) of the cell cycle were deter-BMC Cancer 2006, 6:154 http://www.biomedcentral.com/1471-2407/6/154
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mined from the respective flow cytometry charts. At 6
hours, most cells in both populations were mostly at S
phase while at 12 hours, some cells had gone through S
and G2/M and reached G1. However, the majority of the
cells over-expressing TSPY reached the second S phase
again in 24 hours (Figure 3D) while cells harboring just
the vector alone transited the cell cycle stages more slowly
and had only ~35% of cells reaching the second S phase
(Figure 3C). The synchronization effects seemed to dissi-
pate at 36 and 48 hours in both populations (Figure 3C,
D) and the distributions of their cells in various cell cycle
stages resembled those of exponentially growing cells (as
in Figure 3A, B respectively). Since cells over-expressing
TSPY showed a smaller number in G2/M, such rapid tran-
sition of the cell cycle after the G1/S phase synchroniza-
tion suggested that the cell could progress through the G2/
M phase faster than those harboring the vector alone. To
confirm our postulation that TSPY mediated a fast transit
TSPY enhances tumor growth in athymic nude mice Figure 2
TSPY enhances tumor growth in athymic nude mice. Tumorigenicity assays demonstrated that HeLa Tet-off cells (A) over-
expressing TSPY (- Dox) formed tumor at a faster rate in athymic nude mice than those whose TSPY expression was 
repressed with doxycycline (+ Dox) in the drinking water. Cells harboring the vector alone (pTIG) with or without doxycy-
cline administration or the parental cells (HeLa) showed similar tumor growth rates as that of cells repressing TSPY transgene 
(+Dox) in the host animals. NIH3T3 Tet-off cells are non-tumorigenic cells that normally do not form tumor in athymic hosts. 
Inoculation of these cells over-expressing TSPY (D, – Dox), however, produced small size tumors in 5 of 6 nude mice (E) while 
no tumor was observed in animals inoculated with the same cells and fed with doxycycline-containing water (+Dox). Inocula-
tion of NIH3T3 Tet-off cells harboring the vector alone or parental cells did not produce any tumor in the same hosts fed with 
drinking water with or without doxycycline (data not shown). B and E show examples of athymic nude mice from respective 
inoculations at the end of the experiments. Co-expression of EGFP provided a convenient means to observe directly the 
tumor growth (size) in nude mice (C, F). * Student's t-test analysis indicated that there were statistical significance in differ-
ences between TSPY-expressing cells and vector-alone cells.
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TSPY accelerates G2/M transition in cell cycle Figure 3
TSPY accelerates G2/M transition in cell cycle. Flow cytometry analysis of HeLa Tet-off cells harboring either the vector, pTIG, 
(A) or pTIG-TSPY (B) construct showed a reduced number of cells at G2/M phase in cells over-expressing TSPY (B, -Dox) than 
those repressing TSPY (B, +Dox) or harboring the vector alone (A, +/- Dox). To evaluate the probable reason(s) for such dif-
ferential distribution of cells in various phases of the cell cycle, HeLa Tet-off cells harboring either the vector alone (C) or 
pTIG-TSPY construct (D) were synchronized at G1/S, released into S phase and analyzed similarly with flow cytometry at 0, 6, 
12, 24, 36 and 48 hours after the release. HeLa cells harboring pTIG-TSPY construct (D) progressed at a faster rate than those 
harboring the vector alone (C), and reached in the second S phase within 24 hours after release from the synchronization 
while significant number of cells harboring the vector alone (C) remained in G1 phase at the same time. Such synchronized cell 
cycle progression disappeared towards 36 and 48 hours in both cell populations (C, D). When the cells were synchronized at 
the G2/M phase, released into mitosis, and analyzed similarly with flow cytometry, such accelerated rate of cell cycle progres-
sion were not observed readily between populations harboring the vector alone (E) and TSPY (F). Again, cells over-expressing 
TSPY showed a reduced number(s) at G2/M (e.g. 24 and 36 hour time points in D and all time points in F as compared to those 
in C and E respectively) when they were over-expressing TSPY, resembling those of asynchronous cells (B).
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through G2/M, both HeLa cell populations were synchro-
nized at metaphase by colcemid treatment, released into
cell cycle and analyzed thereafter at 0, 12, 24, 36, and 48
hours with flow cytometry. Our results showed that cells
expressing TSPY progressed through the G1 and S phases
(Figure 3F) at similar rates to those lacking TSPY expres-
sion (Figure 3E). Again, at 36 and 48 hours after their
release, cells in both populations (i.e. harboring TIG-TSPT
and TIG) showed a similar cell cycle stage distribution,
resembling those of exponentially growing and asynchro-
nous cells. We surmise that the facilitating function of
TSPY in the cell cycle was less obvious because the syn-
chronization was at metaphase, immediate beyond the G2
stage in which TSPY is postulated to be effective in expe-
diting cell cycle progression. Nevertheless, one could still
observe fewer percents of cells were at G2/M in cells over-
expressing than those lacking TSPY at these time points,
thereby supporting a role of TSPY at this stage of the cell
cycle, as discussed above.
Cyclin B1 is a mitotic cyclin whose expression is primarily
at late S and G2 [37,38]. Its degradation by the anaphase
promoting complex is essential for the cell to exit mitosis
[39-42]. Hence, the amount of cyclin B1 varies with the
different stages of the cell cycle, i.e. the lowest at G1 and
highest at G2/M. To substantiate the effects of TSPY in cell
cycle progression, we had examined the relative amount
of cyclin B1 in HeLa Tet-off cells harboring either TIG-
TSPY or TIG vector alone, after they were synchronized at
G1/S and released into the cell cycle. Cells were harvested
at 2 hour-intervals, starting at 0 hours and ending at 22
hours. Total protein extracts were prepared from these
cells and processed for western blotting with cyclin B1,
tubulin and TSPY antibodies. Both cell populations
showed minimal level of cyclin B1 at 0 hours immediately
after release from G1/S phase synchronization. The levels
of cyclin B1 in HeLa cells harboring the vector alone
increased gradually starting at 6 hours and peaked at 10
hours and gradually declined through detectable levels to
14–16 hours (Figure 4A). Cells expressing TSPY showed a
detectable level immediately after release from G1/S syn-
chronization (Figure 4B). The level increased gradually
and peaked at 10 hours, but fell rapidly, although still
detectable, thereafter at 12–14 hours. Repeat probing of
the same/similar filters with a tubulin antibody showed
that the loading was relatively even among the various
samples (Figure 4A, lower panel, 4B, middle panel). Cell
harboring the TIG-TSPY transgene expressed TSPY at con-
sistent level throughout the cell cycle (Figure 4B, lower
panel). These findings suggested that TSPY expressing
cells exited the G2/M phase faster than those lacking such
expression.
Differential expression of growth-related genes in HeLa 
cells over-expressing TSPY
To determine how TSPY expression affects cell growth and
cell cycle progression, microarray analysis was performed
on HeLa Tet-off cells expressing TIG-TSPY and compared
with those harboring the TIG vector alone, using the
Affymetrix GeneChip containing 47,000 human tran-
scripts and variants. Our results showed that TSPY and a
limited number of genes were differentially expressed
between the two cell populations. TSPY was expressed at
the highest level while others were consistently affected at
modest levels. The present findings were consistent with
the fact that the two HeLa cell populations were almost
identical, except the high TSPY expression in one and not
the other. To translate sets of differentially regulated genes
at each stage into functional profiles, 181 differentially
expressed genes were analyzed with the web-based pro-
gram, Gene Ontology Tree Machine (GOTM) [43]. Statis-
tical analysis was performed to identify the most
important Gene Ontology categories for the input gene
sets and to suggest their potential biological importance
in the categories. Three biological processes, cell cycle,
phosphate transport, and neuromuscular development,
were preferentially represented among the differentially
expressed genes. Both cell cycle and phosphate transport
could be related to cell growth, and hence are relevant dif-
ferences between TSPY over-expressing and vector alone
cell populations. The exact nature of differential expres-
sion of genes involved in neuromuscular development is
uncertain. However, previous transgenic mouse studies
demonstrated that the human TSPY promoter could be
preferentially active in neurons of pre- and postnatal
brains, suggesting a possible function of this Y chromo-
some gene in neural development [32]. The various cell
cycle related processes affected by the constitutive expres-
sion of TSPY are illustrated (Figure 5). Table 2 lists 25 cell
cycle related genes whose expression was either up- or
down-regulated by over-expression of TSPY. Among the
up-regulated genes were several oncogenes (epidermal
growth factor receptor (ERBB) and members of the WNT
(WNT5A) and RAS families (RAP1A)), growth factors
(PDGFC, EGF-related, ANKRD15, RGC32, NANOS1),
cyclin D2 (CCND2), a co-factor for the hypoxia inducible
factor 1A (EP300), an apoptosis inhibitor (GSPT1) and an
antigen (CD24) highly expressed in small cell lung carci-
noma. The down-regulated genes included an inhibitor
for CDK4/CDK6 (CDKN2B), transforming growth factor
β3, pro-apoptotic factors (CLU and IGFB3), and an inhib-
itor of MAP kinases (DUSP5). In particular, the CCND2
gene (encoding cyclin D2) resides on chromosome 12p
that is frequently amplified and expressed at high levels in
testicular germ cell tumors. Cyclin D2 complexes with
CDK4 or CDK6 to mediate G1/S transition and promote
cell proliferation. Indeed CCND2 expression was up-reg-
ulated in HeLa Tet-off cells over-expressing TSPY. Con-BMC Cancer 2006, 6:154 http://www.biomedcentral.com/1471-2407/6/154
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versely, an inhibitor, CDKN2B, against activation of
CDK4/CDK6 was down-regulated in the same cells,
thereby further supporting the possible role of TSPY in the
CCND2-CDKN2B cell cycle regulation. In additional to
CCND2, another genes, the transmembrane and tetratr-
icopeptide repeats (TMTC1) from chromosome 12p was
also up-regulated by the ectopic expression of TSPY in
HeLa cells. Currently the function of TMTC1 is unknown.
Other tetratricopeptide repeats-containing proteins, such
as subunits cdc16, cdc23 and cdc27 of the anaphase pro-
moting complex (APC), could play important roles in
protein-protein interaction, cell division and receptor sig-
naling [44-46].
To confirm the microarray data, semi-quantitative RT-
PCR was performed on 4 of the up-regulated genes and 4
of the down-regulated genes from Table 2 (bold typed).
Figure 6A showed the results of the RT-PCR from HeLa
Tet-off cells harboring either pTIG or pTIG-TSPY. RGC32,
PDGFC, WNT5A, and CCND2 were confirmed as up-reg-
ulated genes in cells over-expressing TSPY; each showed a
slight increase in fold expression compared to the micro-
array data. CUL1, IGFBP3, TIMP1, and SPARC were con-
firmed as down-regulated genes in cells expressing TSPY
(Figure 6B); each of these also showed a slight change in
fold expression compared to the microarray data. These
results confirmed that cells expressing TSPY could indi-
rectly up-regulate genes involved in the cell growth and
proliferation and down-regulate genes involved in the cell
cycle inhibitors, growth suppressors, and pro-apoptotic
factors.
Discussion
TSPY is a unique gene in the human genome. Although its
transcriptional unit is only approximately 2.8-kb in size,
it is embedded in a 20.4-kb tandemly repeated unit that
shows >98% homology among the members of the TSPY
gene family [47]. Numerous studies suggest that most of
the repeat units are functional capable of coding for a vari-
ety of polymorphic TSPY proteins [28,48,49]. For one
sequenced individual, the TSPY repeat units constitutes
~0.7 MB of DNA on the short arm and only one single
copy on the long arm of the Y chromosome [48,50,51].
Currently, the exact nature of such tandem repetition of a
functional gene and its flanking sequences is uncertain.
However, we surmise that TSPY repeats could be hot spots
for genetic rearrangements and/or transcriptional dysreg-
ulation, resulting in ectopic expression of TSPY variant
transcripts and proteins in tissues that normally do not
express this Y-located gene [9,29,30] and variation in copy
numbers and/or genetic rearrangements [52].
TSPY is a member of a protein superfamily that is defined
by a conserved 191 amino acid domain, designated as
The rapid G2/M transition of HeLa cells over-expressing TSPY is associated with an early degradation of the mitotic cyclin B1 Figure 4
The rapid G2/M transition of HeLa cells over-expressing TSPY is associated with an early degradation of the mitotic cyclin B1. 
HeLa Tet-off cells harboring the vector alone (A) and TIG-TSPY construct (B) were synchronized at G1/S, released into S 
phase, harvested and analyzed with western blotting with various antibodies at 2-hour intervals for 22 hours. The mitotic cyclin 
B1 is synthesized normally in late S phase and G2 and is rapidly degraded before the cell exits mitosis. In cells over-expressing 
EGFP in the vector alone, the levels of cyclin B1 increased at 6 hours after the G1/S release, peaked at 10 hours and gradually 
decreased until 14–16 hours (A, top row) while in those over-expressing both EFGP and TSPY, the levels of cyclin B1 
increased gradually at 2 hours after the G11/S release, peaked at 10 hours and rapidly reduced thereafter (B, top row). The fil-
ters were re-probed with tubulin antibody (A, bottom row; B, middle row) showing relatively even loading of the samples. 
TSPY was uniformly expressed and detected in samples of cells over-expressing this transgene (B, bottom row).
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SET/NAP domain. In yeast, Nap1 can interact specifically
with the B-type cyclin, Clb2, to mediate normal mitotic
functions in fission yeast and to suppress polar bud
growth in budding yeast [19,20]. The mammalian SET
protein can interact with B-type cyclins and has been
shown to regulate the G2/M transition by modulating cyc-
lin B-cyclin-dependent kinase 1 (CDK1) activity [18].
Over-expression of either SET or CDA1 arrested cells at
G2/M phase [12,18], an opposite effect to that of over-
expression of TSPY, in HeLa cells, observed here. TSPY
protein shares significant homology with these proteins at
the SET/NAP domain, but lacks the C-terminal acidic tail
that is found in NAP-1, SET and CDA1. Significantly, a
recent study suggests that the X-located CDA1/DENTT is a
homologue of TSPY and been re-designated as TSPX gene
[13]. It shares significant similarities in exon organization,
except additional exons at both its 5' and 3' termini. Dele-
tion of the acidic domain in CDA1/TSPX eliminates its
inhibitory effects on the G2/M progression in the cell cycle
[12], suggesting the TSPY and TSPX might possess con-
trasting functions on cell cycle modulation.
The main physiological function of TSPY is currently
uncertain. TSPY is expressed in embryonic germ cells and
primarily in spermatogonia and to a reduced level the
spermatids of adult testis [2,4,8,32]. Spermatogonia are a
subset of cells in the testis that are capable of entering
both mitotic and meiotic cell divisions [53]. Hence, TSPY
Diagrammatic illustration of various cell cycle-related biological processes in HeLa cells affected by TSPY over-expression,  compared to those harboring the vector alone, as revealed by the GOTM program Figure 5
Diagrammatic illustration of various cell cycle-related biological processes in HeLa cells affected by TSPY over-expression, 
compared to those harboring the vector alone, as revealed by the GOTM program. Each process is represented by the respec-
tive GO accession number (red) and percents of genes within the 181 differentially expressed genes used in the GOTM analy-
sis.
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has been postulated to serve a physiological function(s) in
stem germ cell proliferation and in directing the sperma-
togonial cells to enter male meiosis [4,9]. Location of
TSPY gene cluster in the critical region for GBY, the only
oncogenic locus on the Y chromosome, establishes it to be
a significant candidate for this special form of germ cell
tumor. Indeed, TSPY has been detected in high levels in
gonadoblastoma tissues as well as those of testicular germ
cell tumors, more common forms of germ cell tumors
[9,24,25]. Additional studies have demonstrated that
TSPY is also expressed in prostate cancers and the andro-
gen responsive LNCaP prostate cancer cell line [9,26],
hepatoma specimens [30], and melanoma samples and
melanoma cell lines [29]. The latter studies further sub-
stantiate the possible role of TSPY in human oncogenesis.
The present studies were designed to address the question
on the effects of ectopic TSPY expression in cell prolifera-
tion and tumorigenesis in immunodeficient mice. Using
the HeLa, a human (female) cervical carcinoma, and
NIH3T3, a non-tumorigenic mouse (lacking a functional
Tspy gene), cell lines and the Tet-off transgene regulation
system, we demonstrated that over-expression of TSPY
potentiates cell proliferation in culture and tumorigenic-
ity in nude mice. Significantly, NIH3T3 cells are non-tum-
origenic, the development of small tumors in nude mice
inoculated with TSPY expressing NIH3T3 cells suggests
that TSPY could potentially play the role of an oncogene.
Our cell cycle analyses demonstrated that TSPY was capa-
ble of mediating the transition of its host cells through G2/
M phase at a faster pace than those lacking TSPY. These
Table 2: List of genes identified in the microarray analysis between HeLa Tet-off cells harboring pTIG-TSPY and those harboring the 
vector pTIG alone
Gene GenBank ID Expression Remarks
TSPY1 NM_003308 26.5 Testis specific protein, Y-linked, stably transfected gene in the cells
MAP2 NM_002374 3.41 Microtubule-associated protein 2, neurogenesis and tumorigenesis
RGC32 NM_014059 2.56 Response gene to complement 32, deregulation of cell cycle required for tumor cell 
growth
PDGFC NM_016205 2.32 Platelet derived growth factor C, a mitogenic factor
MAP1B NM_005909 1.93 Microtubule-associated protein 1B, structural protein, neural development, predictor for breast cancer
EFEMP1 NM_004105 1.79 EGF-containing fibulin-like extracellular matrix protein 1, growth factor
G1P2 NM_005101 1.72 α-interferon inducible protein, IFI-15K, facilitates viral growth
LUM NM_002345 1.62 Lumican, epithelial cell migration and tissue repair
NANOS
1
NM_199461 1.57 Human nanos homolog (of Drosophila), germ stem cell development expressed in spermatogonia and 
spermatocytes in human testis
WNT5
A
NM_003392 1.55 Wingless-type MMTV integration site family member 5A, Wnt gene family, implicated in 
oncogenesis and embryogenesis
CD24 NM_013230 1.55 Small cell lung carcinoma cluster 4 antigen, high expression in SCLC
TMTC1 NM_175861 1.53 Transmembrane and tetratricopeptide repeats containing 1, multi-functional, possibly involved in 
regulation of cell cycle and/or mitosis.
CCND2 NM_001759 1.46 Cyclin D2 complexes with CDK4 or CDK6, G1/S transition, amplified and over-expresses 
in numerous types of tumors
RAP1A NM_002884 1.44 RAS oncogene family member
EGFR NM_005228 1.41 Epidermal growth factor receptor (ERBB oncogene), cell proliferation, amplified and expresses at high 
levels in many tumors
ANKRD
15
NM_015158 1.38 Ankyrin repeat domain 15, tumor cell growth in renal cell carcinoma
GSPT1 NM_002094 1.32 G1 to S phase transition 1, an inhibitor of apoptosis
EP300 NM_001429 1.26 E1A binding protein p300, a co-factor for hypoxia inducible factor 1A
CDKN2
B
NM_004936 0.71 Cyclin-dependent kinase inhibitor 2B (p15), binds to and prevents CDK4/CDK6 activation and G1/S 
progression, tumor suppressor
CUL1 NM_003592 0.68 Cullin 1, involves in deneddylation and modulates G1/S transition
TGFB3 NM_003239 0.67 Transforming growth factor, b3, suppresses tumor formation and blocks cell cycle progression
PTN NM_002825 0.66 Pleiotrophin, neurite growth promoting factor 1, down-regulated in breast cancer
TIMP1 NM_003254 0.64 Tissue inhibitor of metalloproteinase 1, suppresses tumor growth and metastasis
DUSP5 NM_004419 0.58 Dual specificity phosphatase 5, inactivates kinases by dephosphorylation, and negatively regulates MAP 
kinases
SPARC NM_003118 0.56 Secreted protein, acidc cysteine-rich (osteonectin), loss of expression in lung cancers, 
regulates cell proliferation
CLU NM_001831 0.56 Clusterin, proapoptotic in colon cancer, down-regulated in CaP
IGFBP3 NM_000598 0.49 Insulin-like growth factor binding protein 3, pro-apoptotic, its inactivation or repression is 
essential for growth of various tumors
Genes listed in boldface were analyzed with semi-quantitative for RT-PCR (Figure 6).BMC Cancer 2006, 6:154 http://www.biomedcentral.com/1471-2407/6/154
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findings, taken together, support the notion that TSPY is a
growth-promoting gene that increases cell proliferation in
vitro and tumorigenesis in vivo, thereby providing a possi-
ble explanation of abundant TSPY expression in tumor tis-
sues.
Global transcriptional profiling with microarray analyses
further supports the hypothesis that TSPY exerts pro-
growth and proliferative functions in the cell cycle pro-
gression of its host cells. The up-regulation of such pro-
growth genes and oncogenes and down-regulation of
growth inhibitors and apoptotic factors in cells over-
expressing TSPY, as revealed by the microarray studies,
could be confirmed by semi-quantitative RT-PCR analysis.
It is also possible that the differential gene expression is a
result of indirect effects, perhaps through its interaction(s)
with signaling molecules or cell cycle regulators.
Conclusion
Although TSPY expression has been observed in gonado-
blastoma, testicular germ cell tumors, prostate cancer,
hepatomas, and melanomas, no studies have defined its
probable role in human oncogenesis. The present studies
have demonstrated that ectopic TSPY expression expedites
cell cycle progression through shortening of the G2/M
transition. TSPY also up-regulates pro-growth genes/onco-
genes and down-regulates cell cycle inhibitors/apoptotic
factors; however, whether this is a direct or indirect effect
is unknown. Together, these findings provide a possible
mechanism by which TSPY, in collaboration with other
oncogenic events, contributes to tumorigenesis in dys-
functional germ cells and/or susceptible somatic cells/tis-
sues.
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